• SyncroPatch 384/768i

    APC with highest throughput on the market
  • SyncroPatch 384/768i

    384 cells in parallel => upgradable to 768
  • SyncroPatch 384/768i

    True HTS AND Gigaohm seals
  • SyncroPatch 384/768i

    Analysis Software even more powerful than before
  • SyncroPatch 384/768i

    Assay flexibility via high tech

2019 - High Throughput Characterization of KCNB1 Variants Associated with Developmental and Epileptic Encephalopathy

icon sp96  SyncroPatch 768PE (a predecessor model of the SyncroPatch 384/768i) Pre-publication in bioRxiv (2019)

Authors: 
Kang, S.K., Vanoye, C.G., Misra, S.N., Echevarria, D.M., Calhoun, J.D., O’Connor, J.B., Fabre, K.L., McKnight, D., Demmer, L., Goldenberg, P., Grote, L.E., Thiffault, I., Saunders, C., Strauss, K.A., Torkamani, A., van der Smagt, J., van Gassen, K., Carson, R.P., Diaz, J., Leon, E., Jacher, J.E., Hannibal, M.C., Litwin, J., Friedman, N.R., Schreiber, A., Lynch, B., Poduri, A., Marsh, E.D., Goldberg, E.M., Millichap, J.J., George Jr., A.L., Kearney, J.A.

Preprint Source: 
bioRxiv (2019) doi: org/10.1101/637041


Abstract: 

Pathogenic variants in KCNB1, encoding the voltage-gated potassium channel Kv2.1, are associated with developmental and epileptic encephalopathies (DEE). Previous functional studies on a limited number of KCNB1 variants indicated a range of molecular mechanisms by which variants affect channel function, including loss of voltage sensitivity, loss of ion selectivity, and reduced cell-surface expression. We evaluated a series of 17 KCNB1 variants associated with DEE or neurodevelopmental disorder (NDD) to rapidly ascertain channel dysfunction using high-throughput functional assays. Specifically, we investigated the biophysical properties and cell-surface expression of variant Kv2.1 channels expressed in heterologous cells using high-throughput automated electrophysiology and immunocytochemistry-flow cytometry. Pathogenic variants exhibited diverse functional defects, including altered current density and shifts in the voltage-dependence of activation and/or inactivation, as homotetramers or when co-expressed with wild-type Kv2.1. Quantification of protein expression also identified variants with reduced total Kv2.1 expression or deficient cell-surface expression.

Our study establishes a platform for rapid screening of functional defects of KCNB1 variants associated with DEE and other NDDs, which will aid in establishing KCNB1 variant pathogenicity and may enable discovery of targeted strategies for therapeutic intervention based on molecular phenotype.


Download here

Back to Overview

SyncroPatch 384i brochure

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.
More information Ok